SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for 908 Devices (MASS) — May 18, 2022

908 Devices Inc.
Date: May 18, 2022 · CIK: 0001555279 · Accession: 0000000000-22-005397

AI Filing Summary & Sentiment

File numbers found in text: 333-264828

Date
May 18, 2022
Author
Not clearly detected
Form
UPLOAD
Company
908 Devices Inc.

Letter

United States securities and exchange commission logo May 18, 2022 Kevin Knopp Chief Executive Officer 908 Devices Inc. 645 Summer Street Boston, MA 02210 Re:908 Devices Inc. Registration Statement on Form S-3 Filed May 10, 2022 File No. 333-264828 Dear Mr. Knopp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 or Christopher Edwards at 202-551- 6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Minahan

Show Raw Text
United States securities and exchange commission logo
May 18, 2022
Kevin Knopp
Chief Executive Officer
908 Devices Inc.
645 Summer Street
Boston, MA 02210
Re:908 Devices Inc.
Registration Statement on Form S-3
Filed May 10, 2022
File No. 333-264828
Dear Mr. Knopp:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Michael Davis at 202-551-4385 or Christopher Edwards at 202-551-
6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Michael J. Minahan